Log In Sign up
The largest database of trusted experimental protocols

Osi 906

Manufactured by LC Laboratories
Visit Supplier
Sourced in United States

OSI-906 is a small-molecule inhibitor that targets the insulin-like growth factor-1 receptor (IGF-1R) and the insulin receptor (IR). It is designed to inhibit the activity of these receptors, which are involved in cellular growth and survival processes.

Automatically generated - may contain errors

Lab products found in correlation

Tartaric acid, by Merck Group (1 mentions) Vinorelbine, by Merck Group (1 mentions) H1299 cells, by American Type Culture Collection (1 mentions) Lcl161, by Selleck Chemicals (1 mentions) Pim447, by Selleck Chemicals (1 mentions) Paclitaxel, by LC Laboratories (1 mentions) Doxorubicin, by LC Laboratories (1 mentions) Binimetinib, by LC Laboratories (1 mentions) Byl719, by LC Laboratories (1 mentions) Jh 3, by Merck Group (1 mentions) Chir99021, by Selleck Chemicals (1 mentions) Torin 2, by Cayman Chemical (1 mentions)

4 protocols using osi 906

1

Preparation of Inhibitor Stock Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
The mTORi, SIR, EVE and TEM, and the IGF1R/IR inhibitor, OSI-906, were purchased from LC Laboratories (Inc. Woburn, MA, USA). All compounds were dissolved in dimethylsulfoxide (DMSO) 100%, as recommended by the manufacturer, as stock solutions concentrated 10−3M and stored at −20°C. For each experiment, serial dilutions in DMSO 40% were freshly made prior to use.
Pivonello C., Negri M., De Martino M.C., Napolitano M., de Angelis C., Provvisiero D.P., Cuomo G., Auriemma R.S., Simeoli C., Izzo F., Colao A., Hofland L.J, & Pivonello R. (2016). The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. Oncotarget, 7(9), 9718-9731.
+ Open protocol
+ Expand
2

Orthotopic Tumor Xenograft Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
For orthotopic tumor xenograft experiments, flow cytometry sorted CSC-enriched cells were suspended with PBS and mixed with Matrigel (1:1) to a final volume of 100 µl. The mixture was injected into the fourth mammary fat pads of NOD-SCID as described (19 (link)). Tumor sizes were measured with calipers weekly as above and the frequencies of TICs in limiting dilution assays were calculated through the following website: http://bioinf.wehi.edu.au/software/elda/. IGF-1 receptor inhibitor OSI-906 (LC Laboratories) was dissolved in dimethyl sulfoxide (DMSO) at 10mM and stored at −20°C. For OIS-906 treatment, when the tumor volume reached 600 mm3, mice were randomly assigned to vehicle (25mM tartaric acid (Sigma) in water) or OSI-906 (50 mg/kg) treatments by oral gavage once a day for 14 days. At the end of treatment, tumors were collected for flow cytometry analysis, mammosphere culture assays as well as paraffin/frozen sections for immunostaining analysis.
Yang Y., Leonard M., Zhang Y., Zhao D., Mahmoud C., Khan S., Wang J., Lower E.E, & Zhang X. (2017). HER2-driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1. Cancer research, 78(2), 422-435.
+ Open protocol
+ Expand
3

Combination Therapy for Lung Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Doxorubicin, OSI-906, BYL719, binimetinib, and paclitaxel were purchased from LC Laboratories (Woburn, MA). PIM447 and LCL161 were obtained from Selleck Chemicals (Houston, TX). Vinorelbine was purchased from Sigma-Aldrich (St. Louis, MO). THZ1 was purchased from Cayman Chemical Company (Ann Arbor, MI). Human lung carcinoma PC9 cells were obtained from Sigma-Aldrich, and H1299 cells were provided from ATCC (Manassas, VA). All cell lines were grown in RMPI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin, at 37 °C and 5% CO2.
Bae S.Y., Guan N., Yan R., Warner K., Taylor S.D, & Meyer A.S. (2020). Measurement and models accounting for cell death capture hidden variation in compound response. Cell Death & Disease, 11(4), 255.
+ Open protocol
+ Expand
4

Synthesis and Purification of Bioactive Compounds

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Bioactive ILP3 was produced by chemically synthesizing the A and B chains using standard Fmoc chemistry followed by formation of the correct interchain disulfide bonds as previously reported (Brown et al. 2008 (link)). Recombinant OEH was produced in Escherichia coli and purified by HPLC (Wen et al., 2010 (link); Gulia-Nuss et al. 2015 (link); Vogel et al. 2015 (link)). Stock solutions of 20E and JH III (Sigma) were solubilized in ethanol. OSI-906 (LC Laboratories, Woburn, MA), Torin 2 (Cayman, Ann Arbor, MI), and CHIR-99021 (Selleck Chemicals, Houston, TX) prepared in dimethyl sulfoxide (DMSO) were diluted in Sf-900 II serum free medium (= Sf900, Gibco) or buffered saline to contain 0.8% or less DMSO.
Valzania L., Mattee M.T., Strand M.R, & Brown M.R. (2019). Blood feeding activates the vitellogenic stage of oogenesis in the mosquito Aedes aegypti through inhibition of glycogen synthase kinase 3 by the insulin and TOR pathways. Developmental biology, 454(1), 85-95.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!